BioCentury
ARTICLE | Clinical News

Botox onabotulinumtoxinA regulatory update

October 8, 2012 7:00 AM UTC

Allergan said the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) approved Botox onabotulinumtoxinA to manage urinary incontinence in adult patients with neurogenic detrusor overactivity (NDO) due to subcervical spinal cord injury (SCI) or multiple sclerosis (MS) who are not adequately managed with anticholinergics. ...